Bill McCarthy, Donald Loveday, and Doug Hovey of SPI Pharma discuss the recent expansion of SPI’s portfolio to include specialized excipients for advanced controlled-release and multiparticulate formulations and how they help enable patient-friendly regimens.
.svg)
